The Changing Landscape of Therapy in HER2-Low and Ultralow Breast Cancer (Part 1)

from Medical News Podcast · host PeerDirect Publishing

Dr. Tiffany Traina and Dr. Josh Drago discuss the evolving treatment landscape for HER2-low and ultralow breast cancer, highlighting how pivotal trials like Destiny Breast-04 and Destiny Breast-06 have demonstrated significant efficacy improvements with trastuzumab deruxtecan while emphasizing the need to balance its toxicity profile with benefits for individual patients.

Episode metadata supplied by the publisher feed · Published Dec 9, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

The Changing Landscape of Therapy in HER2-Low and Ultralow Breast Cancer (Part 1)

0:00 11:45

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Medical News Podcast?

This episode is 11 minutes long.

When was this Medical News Podcast episode published?

This episode was published on December 9, 2025.

Can I download this Medical News Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!